반응식
[C:1]([NH:4][C:5]1[C:10]2[C:11](=[O:16])[CH2:12][CH2:13][CH2:14][CH2:15][C:9]=2[CH:8]=[CH:7][CH:6]=1)(=[O:3])[CH3:2].[C:17]([NH:20]C1C=CC=C2C=1C(=O)CCC2)(=[O:19])[CH3:18]>>[C:1]([NH:4][C:5]1[C:10]2[C:11](=[O:16])[CH:12]([NH:20][C:17](=[O:19])[CH3:18])[CH2:13][CH2:14][CH2:15][C:9]=2[CH:8]=[CH:7][CH:6]=1)(=[O:3])[CH3:2]참가 물질
3
실험 절차
The reaction was carried out in the same manner as in Example 1-(2), except that 270 mg of the compound prepared in (2) above was used instead of 8-acetylamino-1-tetralone of Example 1-(2). The reaction mixture obtained by the post-treatment was further reacted in the same manner as in Example 1-(3) and post-treated to produce 126 mg of the title compound.
후처리
- customThe reaction mixture obtained by the post-treatment
- additionpost-treated
출처 및 근거
- ORD 기록
- ord-a6c9eea160d542618b7334d21eca165d
- 출처 데이터셋
- uspto-grants-1998_11
- 특허 번호
- US05834476
연결된 노트
불러오는 중…